Simvastatin suppresses the differentiation of C2C12 myoblast cells via a Rac pathway.
Statins, which are known as cholesterol-lowering drugs, have several additional effects including the enhancement of bone formation and the stimulation of smooth muscle cell proliferation. In this study, we investigated the signal pathway of simvastatin operating in C2C12 myoblast cells. Myotube formation of C2C12 cells was efficiently blocked by 1 muM simvastatin, and mevalonic acid was able to cancel this effect. Geranylgeranyl pyrophosphate restored the myotube formation, whereas farnesyl pyrophosphate did not. These findings demonstrate that the Rho family, such as Rho, Rac and Cdc42, occurring downstream of geranylgeranyl pyrophosphate in the mevalonic acid pathway, was involved in the simvastatin-mediated blockage of myotube formation. An inhibitor of Rho kinase did not influence the myotube formation; whereas an inhibitor of Rac blocked this process. Taken together, we conclude that the differentiation of C2C12 cells into myotubes was blocked by simvastatin through the pathway mediated by Rac, not by Rho.
Baba
Tomomi T
TT
Department of Oral Molecular Biology, Unit of Basic Medical Sciences, Course of Medical and Dental Sciences, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, 852-8588, Japan. baba@nagasaki-u.ac.jp
Nemoto
Takayuki K
TK
Miyazaki
Toshihiro
T
Oida
Shinichiro
S
D000469:Alkaline Phosphatase / Q000378:metabolism; D000577:Amides / Q000494:pharmacology; D000634:Aminoquinolines / Q000494:pharmacology; D000818:Animals; D055396:Bone Morphogenetic Protein 2 / Q000235:genetics / Q000494:pharmacology; D002454:Cell Differentiation / Q000187:drug effects*; D002478:Cells, Cultured; D015870:Gene Expression / Q000187:drug effects; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000494:pharmacology; D008798:Mevalonic Acid / Q000494:pharmacology; D018485:Muscle Fibers, Skeletal / Q000166:cytology / Q000378:metabolism; D032448:Myoblasts, Skeletal / Q000166:cytology / Q000187:drug effects* / Q000378:metabolism; D018008:Myogenin / Q000235:genetics; D010006:Osteoblasts / Q000166:cytology / Q000187:drug effects / Q000378:metabolism; D011106:Polyisoprenyl Phosphates / Q000494:pharmacology; D047428:Protein Kinase Inhibitors / Q000494:pharmacology; D011725:Pyridines / Q000494:pharmacology; D011743:Pyrimidines / Q000494:pharmacology; D011994:Recombinant Proteins / Q000494:pharmacology; D012717:Sesquiterpenes / Q000494:pharmacology; D015398:Signal Transduction / Q000187:drug effects*; D019821:Simvastatin / Q000494:pharmacology*; D020744:rac GTP-Binding Proteins / Q000037:antagonists & inhibitors / Q000378:metabolism*; D054460:rho-Associated Kinases / Q000037:antagonists & inhibitors
D000577:Amides; D000634:Aminoquinolines; C525718:BMP2 protein, human; D055396:Bone Morphogenetic Protein 2; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D018008:Myogenin; C487513:NSC 23766; D011106:Polyisoprenyl Phosphates; D047428:Protein Kinase Inhibitors; D011725:Pyridines; D011743:Pyrimidines; D011994:Recombinant Proteins; D012717:Sesquiterpenes; C108830:Y 27632; C004808:farnesyl pyrophosphate; D019821:Simvastatin; D054460:rho-Associated Kinases; D000469:Alkaline Phosphatase; D020744:rac GTP-Binding Proteins; C002963:geranylgeranyl pyrophosphate; D008798:Mevalonic Acid
Am Heart J. 1999 Aug;138(2 Pt 2):S177-82
10426879
J Biol Chem. 2005 Apr 8;280(14):13503-11
15705589
JAMA. 1997 Jul 23-30;278(4):313-21
9228438
J Cell Biochem. 2004 Jun 1;92(3):458-71
15156558
Nature. 1977 Dec 22-29;270(5639):725-7
563524
Circulation. 1995 Dec 1;92(11):3172-7
7586300
Biochem Biophys Res Commun. 1999 Nov 19;265(2):361-5
10558872
J Pharm Pharmacol. 2005 Nov;57(11):1475-84
16259781
Am Heart J. 2004 Jun;147(6):956-65
15199341
J Neurol Sci. 2005 Mar 15;229-230:269-73
15760650
Proc Natl Acad Sci U S A. 2001 May 8;98(10):5856-61
11296263
Biochem Biophys Res Commun. 2000 May 19;271(3):688-92
10814523
Annu Rev Biochem. 1996;65:241-69
8811180
J Mol Cell Cardiol. 2007 Aug;43(2):168-76
17560598
Science. 1988 Dec 16;242(4885):1528-34
3201241
Biochem Biophys Res Commun. 2001 Sep 21;287(2):337-42
11554731
J Cell Biol. 1994 Dec;127(6 Pt 1):1755-66
7798324
Nat Med. 2000 Dec;6(12):1399-402
11100127
Am J Geriatr Cardiol. 2002 Jan-Feb;11(1):48-55
11773716
Biochem Biophys Res Commun. 2001 Jun 8;284(2):478-84
11394905
Nat Med. 2000 Sep;6(9):1004-10
10973320
Oral Dis. 2006 Mar;12(2):85-101
16476028
Exp Cell Res. 1997 Feb 1;230(2):342-51
9024793
J Cell Biochem. 2007 Aug 15;101(6):1430-8
17252541
J Am Coll Cardiol. 2000 Jan;35(1):1-10
10636252
Circulation. 2006 Jul 4;114(1 Suppl):I566-72
16820639
Science. 1999 Dec 3;286(5446):1946-9
10583956
J Biol Chem. 2002 May 3;277(18):15309-16
11839765
Biochem Biophys Res Commun. 2004 Mar 12;315(3):636-42
14975748
Biochem Biophys Res Commun. 2003 Aug 29;308(3):458-62
12914771
J Cardiovasc Pharmacol. 1998 May;31(5):773-8
9593078
Biochem Biophys Res Commun. 1990 Oct 15;172(1):295-9
1699539
Proc Natl Acad Sci U S A. 2001 May 8;98(10):5815-20
11309494
Am J Respir Cell Mol Biol. 2006 Dec;35(6):722-9
16858009
Calcif Tissue Int. 2000 Nov;67(5):416-21
11136541
Circulation. 2006 Jul 4;114(1 Suppl):I547-52
16820635
FASEB J. 2005 Dec;19(14):1986-97
16319142
Circulation. 2000 Jan 18;101(2):207-13
10637210
Bone. 2003 Oct;33(4):652-9
14555271
J Toxicol Sci. 2007 Feb;32(1):57-67
17327694
Circ Res. 1998 Sep 7;83(5):490-500
9734471